Effect of pioglitazone on urinary liver‐type fatty acid‐binding protein concentrations in diabetes patients with microalbuminuria

Diabetes/Metabolism Research and Reviews - Tập 22 Số 5 - Trang 385-389 - 2006
Tsukasa Nakamura1, Takeshi Sugaya2, Yasuhiro Kawagoe1, Yoshihiko Ueda3, Hikaru Koide4
1Department of Medicine, Shinmatsudo Central General Hospital, Chiba, Japan
2Research Unit for Organ Regeneration, Riken Kobe Institute, Hyogo, Japan
3Department of Pathology, Koshigaya Hospital, Dokkyo University School of Medicine, Saitama, Japan
4Department of Medicine, Koto Hospital, Tokyo, Japan

Tóm tắt

AbstractBackgroundUrinary liver‐type fatty acid‐binding protein (L‐FABP) is a useful marker for renal tubulointerstitial injury. Pioglitazone is reported to be effective in early diabetic nephropathy. The aim of the present study was to determine whether pioglitazone affects urinary L‐FABP levels in diabetic nephropathy patients with microalbuminuria.MethodsSixty‐eight patients with type 2 diabetes and microalbuminuria were randomized to a 12‐month treatment with pioglitazone (30 mg/d, n = 17), glibenclamide (5 mg/d, n = 18), voglibose (0.6 mg/d, n = 17), or nateglinide (270 mg/d, n = 16). Pre‐ and posttreatment urinary albumin excretion (UAE) and urinary L‐FABP concentrations were compared between the four treatment groups and 40 age‐matched healthy subjects.ResultsPretreatment UAE and urinary L‐FABP levels differed little between the four groups. UAE and urinary L‐FABP levels were significantly greater in the diabetes patients than in the healthy subjects (UAE: p < 0.001; L‐FABP: p < 0.01). After 6 and 12 months, UAE and urinary L‐FABP were significantly lower in the pioglitazone treatment group than in the other treatment groups (UAE: 6 months, p < 0.01 and 12 months, p < 0.001; L‐FABP: 6 months, p < 0.05 and 12 months, p < 0.01).ConclusionsPioglitazone, but not glibenclamide, voglibose, or nateglinide, appears to be effective in reducing UAE and the urinary L‐FABP level, suggesting that pioglitazone has a specific role in ameliorating both glomerular and tubulointerstitial lesions associated with early diabetic nephropathy. Copyright © 2006 John Wiley & Sons, Ltd.

Từ khóa


Tài liệu tham khảo

10.1111/j.1463-1326.2004.00382.x

10.1055/s-2004-830527

10.1016/j.metabol.2004.06.016

10.1016/S1056-8727(00)00124-0

10.1016/j.metabol.2004.05.013

Phillips AO, 2002, Diabetic nephropathy: the central role of renal proximal tubular cells in tubulointerstitial injury, Histol Histopathol, 17, 247

10.1007/s11892-003-0013-1

10.1016/S0002-9440(10)63384-6

10.1111/j.1523-1755.2004.00653.x

10.1002/dmrr.473

10.2337/diacare.26.8.2231

10.2337/diacare.25.4.658

10.1111/j.1464-5491.2004.01272.x

10.1016/j.lab.2003.08.001

10.1111/j.1523-1755.2004.00624.x

10.1358/dnp.2003.16.2.740244

10.1046/j.1523-1755.2002.00277.x

10.1681/ASN.2004040278

10.1046/j.1523-1755.2001.00766.x

10.1111/j.1523-1755.2004.00574.x

10.1097/01.ASN.0000068626.23485.E0

10.1073/pnas.88.6.2051

10.1038/347645a0

10.1210/jc.2003-030861

Thông tin
Thông tin xuất bản

Diabetes/Metabolism Research and Reviews

Tập 22 Số 5

385-389

Thông tin tác giả